文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

通过分次内兆伏-千伏前列腺位置监测减少放疗后泌尿系统毒性

Reduction of Postradiation Therapy Urinary Toxicity Via Intrafractional Megavoltage-Kilovoltage Prostate Location Monitoring.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-08-13

研究假设自制兆伏-千伏影像引导(MKIG)系统在立体定向体部放疗(SBRT)中确保前列腺正确定位可避免非靶组织受照并减少毒性。2017至2019年150例前列腺癌患者接受SBRT并采用MKIG监测,对比121例采用分次内运动审查(IMR)的患者。MKIG组≥2级泌尿毒性发生率低于IMR组(10.7% vs 19.8%,P=0.047)。

要点

  • MKIG组治疗移位次数多于IMR组(1.09 vs 0.28),分次平均照射时间更长(579±205秒 vs 357±117秒)。
  • MKIG组因监测导致的移位中75%≤3 mm,IMR组为51%,提示MKIG检测并纠正了更小的偏差。
  • MKIG组≥2级泌尿毒性发生率为10.7%,IMR组为19.8%(P=0.047)。

核心结论

  • 自动定量MKIG对工作流程影响极小,在前列腺SBRT定位中优于IMR,并与晚期泌尿毒性临床显著降低相关。
  • 需要采用随机试验进一步临床测试以验证对结局的影响。

研究设计与样本

  • 研究纳入2017至2019年150例接受SBRT的前列腺癌患者,采用自制三维MKIG平台实时追踪植入基准标记进行监测。
  • 对比队列为121例接受相同剂量方案和治疗技术但采用IMR管理的患者。
  • 中位随访时间3.7年(范围0.2-8.2年)。

主要发现

  • MKIG组治疗移位次数为1.09次,IMR组为0.28次;MKIG组分次平均照射时间为579±205秒,IMR组为357±117秒。
  • MKIG组75%的移位≤3 mm,IMR组为51%。
  • MKIG组≥2级泌尿毒性发生率为10.7%,IMR组为19.8%(P=0.047)。
  • 晚期泌尿毒性多因素分析仅选择放疗前国际前列腺症状评分高(>7)(P<0.043)和使用MKIG(P<0.029)。

关键数值与推荐

  • 当基准标记位移超过1.5 mm阈值时,运动轨迹提醒治疗师中断并重新定位前列腺。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要采用随机试验进一步临床测试以验证对结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We hypothesized that an in-house developed system using megavoltage and kilovoltage image guidance (MKIG) to ensure correct prostate positioning during stereotactic body radiation therapy (SBRT) could potentially avoid unwanted doses to nontarget tissues, leading to reduced toxicities. METHODS AND MATERIALS: We built a 3-dimensional MKIG platform that accurately tracks prostate implanted fiducials in real time and clinically translated the system to replace a commercial approach, intrafraction motion review (IMR), which only tracks fiducials in the 2-dimensional kilovoltage views. From 2017 to 2019, 150 patients with prostate cancer were treated with SBRT and monitored using MKIG. The motion trace of the fiducials alerts therapists to interrupt and reposition the prostate when displacement exceeds a 1.5 mm threshold. A comparison cohort of 121 patients was treated with the same dose regimen and treatment technique but managed by IMR. Statistics of intrafractional patient shifts and delivery time were collected to evaluate the workflow efficacy. The incidence of grade ≥2 urinary toxicities was analyzed to assess clinical complications. The median follow-up time was 3.7 years (0.2-8.2 years). RESULTS: MKIG treatments had more treatment shifts (1.09 vs 0.28) and a longer average delivery time per fraction (579 ± 205 seconds vs 357 ± 117 seconds) than IMR treatments. Three-quarters (75%) of shifts resulting from MKIG were ≤3 mm, versus 51% in IMR, indicating that MKIG detected and corrected smaller deviations. The incidence of grade ≥2 urinary toxicity was lower in the MKIG than the IMR cohort: 10.7% versus 19.8% (P = .047). On multivariate analysis of late urinary toxicity, only high (>7) preradiation therapy international prostate symptom score (P < .043) and the use of MKIG were selected (P < .029). CONCLUSIONS: Automated and quantitative MKIG introduced minimal workflow impact and was superior to IMR in localizing the prostate during SBRT, which correlated with a clinically significant reduction in late urinary toxicity. Further clinical testing using randomized trials will be required to validate the impact on outcomes.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhang P, Happersett L, Burleson S, et al. Reduction of Postradiation Therapy Urinary Toxicity Via Intrafractional Megavoltage-Kilovoltage Prostate Location Monitoring. Int J Radiat Oncol Biol Phys. 2024. PMID: 39147205. doi:10.1016/j.ijrobp.2024.07.2325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。